WAL-DRAM 2 — Class III drug recall D-0324-2020
Terminated recall by Sato Pharmaceutical Inc., reported 2019-11-20, distributed nationwide. Subpotent Drug
| Recall number | D-0324-2020 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sato Pharmaceutical Inc., Torrance, CA, United States |
| Recall initiated | 2019-10-01 |
| Classified | 2019-11-13 |
| Reported by FDA | 2019-11-20 |
| Terminated | 2020-08-18 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| UPC / GTIN / UDI-DI | 00311917183282, 00311917203188 |
| NDC | 00363-1407, 00363-1407-01, 00363-1407-02 |
| Expiration dates | 2021-02-20, 2021-05-20, 2021-07-20, 2021-11-20 |
Product
WAL-DRAM 2 (meclizine Hydrochloride) 25 mg tablets, packaged in a) 12 count (NDC 0363-1407-01, UPC 3 11917-18328 2 ) and b) 18-count boxes (NDC 0363-1407-02, UPC 3 11917-20318 8) Distributed by Sato Pharmaceutical INC. 20695 S. Western Ave., Suite 240 Torrence, CA 90501,
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0324-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.